What question did this study set out to answer?

This research aims to evaluate how the effectiveness of zoledronate varies by the stage of avascular necrosis and bone resorption activity.

February 11, 2026Open Access

Effect of zoledronate on avascular necrosis of the femoral head according to disease stage and bone resorption activity

LMLotta MoksiUniversity of Oulu NSNiko SissalaUniversity of Oulu OROjala Risto

Key Points

This research aims to evaluate how the effectiveness of zoledronate varies by the stage of avascular necrosis and bone resorption activity.
Analyzed treatment outcomes of zoledronate in male patients with varying stages of osteonecrosis.
Categorized disease stages using ARCO classification (I-IV).
Monitored ICTP levels to assess bone resorption activity before and after treatment.
Early-stage treatment (ARCO I-II) shows improved outcomes with zoledronate.
Advanced disease (ARCO III-IV) shows poor response to treatment.
Elevated ICTP levels post-treatment correlate with higher treatment failure rates.

Abstract

Zoledronate treatment is more likely to be effective in male patients with early-stage osteonecrosis (ARCO I-II), whereas advanced-stage disease (ARCO III-IV) may not respond well. Moreover, an accelerated bone resorption rate, indicated by elevated ICTP levels after zoledronate infusion, is associated with an increased risk of treatment failure.

AIに質問

Bookmark

View Full Paper